An in vitro microfluidic gut-on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and gastrointestinal epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal tissue, e.g., Crohn's disease, colitis and other inflammatory gastrointestinal disorders. These multicellular, layered microfluidic gut-on-chip further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal deuodejeum, small intestinal ileium, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

A cardiac organoid containing 3-D matter of adult human heart tissue.

A method for producing a disease model, including a step of introducing a cancer cell or fibroblast into a recellularized organ or tissue is provided by the present invention.

An oral biology model which comprises biofilm, oral epithelial tissue and a suspension of neutrophil-like cells in media is disclosed. The biofilm, which comprises oral bacteria, is produced by culturing oral bacteria on a solid substrate. The oral epithelial tissue may be gingival epithelial tissue to model the gingival crevice or buccal epithelial tissue to model the oral check. The suspension of neutrophil-like cells in media comprises neutrophil-like cells that are differentiated HL60 cells induced to a neutrophil-like phenotype by treatment with retinoic acid. Methods of using the oral biology model to test and compare compounds and formulations or to screen compounds and formulations for their effect on release of inflammatory signals, their effect on biofilm and oral bacteria and/or their effect on the cellular components are disclosed.

A method for preparing an autologous pancreatic tumor organoid and immune cell co-culture is provided, including: culturing pancreatic tumor cells obtained from a patient in a culture medium to provide a pancreatic tumor organoid and an organoid-conditioned medium; pulsing dendritic cells derived from the patient with a portion of the organoid-conditioned medium; contacting the pulsed dendritic cells with cytotoxic T lymphocytes (CTLs) obtained from the patient in the organoid-conditioned medium to activate the CTLs; isolating the activated CTLs; and co-culturing the pancreatic tumor organoid with the activated CTLs and myeloid derived suppressor cells (MDSCs) derived from the patient, to obtain an autologous pancreatic tumor organoid and immune cell co-culture that mimics the patient's pancreatic tumor microenvironment. Also provided are co-cultures obtained by the disclosed methods and methods of screening and determining whether a patient is likely to benefit from a candidate therapy.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent renal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of assessing the effect of an agent on renal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are models of renal disorder. In one embodiment, disclosed are models of renal fibrosis, comprising a three-dimensional, engineered, bioprinted, biological renal tubule model. Also disclosed are methods of making the model of renal disorder. In one embodiment disclosed are methods of making the model of renal fibrosis comprising contacting a three-dimensional, engineered, bioprinted, biological renal tubule model with an agent that is capable of inducing interstitial fibrotic tissue formation.

Disclosed herein are recellularized livers prepared from decellularized liver extracellular matrices. Also disclosed herein are kits and systems comprising a recellularized liver as described herein. Also disclosed herein are methods of recellularizing livers from decellularized liver extracellular matrices.

Provided are three-dimensional pancreatic organoids derived from the pancreas of a genetically mutated mouse, a method for producing the three-dimensional pancreatic organoids, the use of the three-dimensional pancreatic organoids for drug effect verification and/or drug screening, and a universally applicable standardized drug effect evaluation method/drug screening method.

A composition for inducing dedifferentiation from cancer cells to cancer stem cells comprising a ribosome-activating inhibitor as an active ingredient, a method of culturing a cancer organoid based thereon and an anticancer drug screening platform, and the increase of colorectal cancer stem cell group induced by the exposure of ribosome-inactivating stress was regulated by the ATF3 gene.

Methods and compositions for determining multiplex interactions between drugs and drug transporters using an intestinal tissue explant are provided.